The Innovative Medicines Initiative's New Drugs for Bad Bugs programme: European public–private partnerships for the development of new strategies to tackle antibiotic resistance

Meeting the societal need for new antibiotics: the challenges for the pharmaceutical industry

(2015) Seamus O'Brien   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Antibiotic research and development: business as usual?

(2015) S. Harbarth et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

A Novel Anti-PcrV Antibody Providing Enhanced Protection against Pseudomonas aeruginosa in Multiple Animal Infection Models

(2014) Paul Warrener et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

UK and European Union public and charitable funding from 2008 to 2013 for bacteriology and antibiotic research in the UK: an observational study

(2014) Eilis C Bragginton et al.   LANCET INFECTIOUS DISEASES

Drug development: Time for teamwork

(2014) Mike May   NATURE

Momentum builds around new antibiotic business models

(2014) Asher Mullard   NATURE REVIEWS DRUG DISCOVERY

ND4BB: addressing the antimicrobial resistance crisis

(2014) John H. Rex   NATURE REVIEWS MICROBIOLOGY

TRANSLOCATION Project: How to Get Good Drugs into Bad Bugs

(2014) R. A. Stavenger et al.   Science Translational Medicine

A multifunctional bispecific antibody protects against Pseudomonas aeruginosa

(2014) A. DiGiandomenico et al.   Science Translational Medicine

Overcoming the current deadlock in antibiotic research

(2014) Till F. Schäberle et al.   TRENDS IN MICROBIOLOGY

Human Simulated Studies of Aztreonam and Aztreonam-Avibactam To Evaluate Activity against Challenging Gram-Negative Organisms, Including Metallo-β-Lactamase Producers

(2013) Jared L. Crandon et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Assessment of an Anti-Alpha-Toxin Monoclonal Antibody for Prevention and Treatment of Staphylococcus aureus-Induced Pneumonia

(2013) L. Hua et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Single-Dose Safety, Tolerability, and Pharmacokinetics of the Antibiotic GSK1322322, a Novel Peptide Deformylase Inhibitor

(2013) Odin J. Naderer et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Activity of BAL30072 alone or combined with  -lactamase inhibitors or with meropenem against carbapenem-resistant Enterobacteriaceae and non-fermenters

(2013) S. Mushtaq et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

A comprehensive regulatory framework to address the unmet need for new antibacterial treatments

(2013) John H Rex et al.   LANCET INFECTIOUS DISEASES

Staphylococcus aureus Alpha Toxin Suppresses Effective Innate and Adaptive Immune Responses in a Murine Dermonecrosis Model

(2013) Christine Tkaczyk et al.   PLoS One

Identification of Anti-Alpha Toxin Monoclonal Antibodies That Reduce the Severity of Staphylococcus aureus Dermonecrosis and Exhibit a Correlation between Affinity and Potency

(2012) C. Tkaczyk et al.   Clinical and Vaccine Immunology

Identification of broadly protective human antibodies toPseudomonas aeruginosaexopolysaccharide Psl by phenotypic screening

(2012) Antonio DiGiandomenico et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Society's failure to protect a precious resource: antibiotics

(2011) Jean Carlet et al.   LANCET

In Vitro Properties of BAL30072, a Novel Siderophore Sulfactam with Activity against Multiresistant Gram-Negative Bacilli

(2010) M. G. P. Page et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY